Novobind Overview
- Year Founded
-
2012
- Status
-
Private
- Employees
-
20
- Latest Deal Type
-
2ndary - Private
- Investors
-
12
Novobind General Information
Description
Operator of an agri-biotech company intended to combat rising resistance to anti-infectives and the build-up of dangerous residues in the environment. The company develops next-generation biologics that target and neutralize the specific bacteria, viruses, and parasites that cause intestinal ailments in livestock, aquaculture, and pets, enabling animal sector businesses to reduce wastage caused by bacteria, viruses, and parasites in aquatic and terrestrial livestock production.
Contact Information
Website
www.novobind.comCorporate Office
- 1021 West Hastings
- MNP Tower 9th Floor
- Vancouver, British Columbia V6E 0C3
- Canada
Corporate Office
- 1021 West Hastings
- MNP Tower 9th Floor
- Vancouver, British Columbia V6E 0C3
- Canada
Novobind Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 5. Later Stage VC (Series A) | 01-Oct-2020 | Completed | Generating Revenue | |||
| 4. Seed Round | Completed | Generating Revenue | ||||
| 3. Accelerator/Incubator | 01-Mar-2017 | Completed | Generating Revenue | |||
| 2. Grant | 03-Jun-2014 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | Completed | Generating Revenue |
Novobind Patents
Novobind Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024092360-A1 | Antibodies against aquaculture disease-causing agents and uses thereof | Inactive | 03-Nov-2022 | ||
| WO-2023205876-A1 | Antibodies against disease causing agents of plants and uses thereof | Inactive | 29-Apr-2022 | ||
| WO-2023168357-A2 | Antibodies against disease-causing agents applied to plant vascular systems | Inactive | 03-Mar-2022 | ||
| WO-2023168357-A3 | Antibodies against disease-causing agents applied to plant vascular systems | Inactive | 03-Mar-2022 | ||
| CA-3140739-A1 | Antibodies against disease causing agents of poultry and uses thereof | Pending | 20-May-2019 | C07K16/20 |
Novobind Signals
Novobind Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Agribusiness Advisors | Venture Capital | Minority | ||
| Ark Canada Investment Group | Family Office | Minority | ||
| Invest Nova Scotia | Venture Capital | Minority | ||
| Lallemand | Corporation | Minority | ||
| Little Green Bamboo Capital | Venture Capital | Minority |
Novobind FAQs
-
When was Novobind founded?
Novobind was founded in 2012.
-
Where is Novobind headquartered?
Novobind is headquartered in Vancouver, Canada.
-
What is the size of Novobind?
Novobind has 20 total employees.
-
What industry is Novobind in?
Novobind’s primary industry is Other Pharmaceuticals and Biotechnology.
-
Is Novobind a private or public company?
Novobind is a Private company.
-
What is Novobind’s current revenue?
The current revenue for Novobind is .
-
Who are Novobind’s investors?
Agribusiness Advisors, Ark Canada Investment Group, Invest Nova Scotia, Lallemand, and Little Green Bamboo Capital are 5 of 12 investors who have invested in Novobind.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process